Zinecard News and Research

RSS

Zinecard is a drug used to reduce heart damage in women given doxorubicin for breast cancer that has spread. It is also being studied in the treatment of cancer. Zinecard contains the active ingredient dexrazoxane. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor

Cardio-protective drug during cancer treatment may prevent heart damage in children

About 75 percent of children with leukemia who take chemotherapy face life-threatening heart problems as they age, but an international study led by a University of Rochester Medical Center investigator shows that giving a cardio-protective drug during cancer treatment may prevent the damage.

6 Jun 2012

FDA approves Mylan's generic Dexrazoxane for Injection ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.

28 Nov 2011

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

A potent chemotherapy that is highly effective in treating the most common form of childhood leukemia can significantly harm the heart, but findings from a multi-center study

9 Jul 2004